Tumor Anti-Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment

Area of Science:

• Oncology
• Immunology
• Vascular Biology

Background:

• Immunotherapy is a cancer treatment with limited response rates in many patients.
• Abnormal tumor vasculature creates an immunosuppressive tumor microenvironment, hindering immunotherapy.
• Anti-angiogenic therapy can remodel the tumor immune microenvironment and enhance anti-cancer effects.

Purpose of the Study:

• To review current research on anti-tumor angiogenesis drugs.
• To discuss the impact of tumor vasculature on immune cells within the tumor microenvironment (TME).
• To highlight clinical advances in combining anti-angiogenic therapy with immunotherapy.

Main Methods:

• Literature review of anti-tumor angiogenesis drugs and their effects on tumor vasculature.
• Analysis of the relationship between tumor blood vessels and immune cell infiltration in the TME.
• Examination of clinical trial data for combination therapies involving anti-angiogenic agents and immunotherapies.

Main Results:

• Vascular normalization can improve tumor perfusion and immune cell infiltration, thereby enhancing immunotherapy.
• Anti-angiogenic therapy can modulate the immune microenvironment, leading to improved anti-tumor efficacy.
• Combining anti-angiogenic therapy with immunotherapy shows promise in clinical settings.

Conclusions:

• Targeting tumor vasculature through vascular normalization is a promising strategy to enhance immunotherapy.
• The combination of anti-angiogenic therapy and immunotherapy represents a potent approach for cancer treatment.
• Further research into targeting both tumor blood vessels and immune cells is crucial for improving cancer patient outcomes.